As cancer incidence continues to rise around the world, the National Cancer Institute (NCI) has taken on a significant role in global cancer control efforts. NCI Divisions, Offices, and Centers (DOCs) support global health research across the continuum of cancer and collaborate with many international agencies to translate research results into practice. To celebrate NCI’s increasing international presence, the Center for Global Health (CGH) hosted the 2nd annual Intra-NCI Global Cancer Research Day (GCR2016) on October 6 to highlight NCI’s advances in cancer prevention and screening worldwide. This one-day event was filled with exciting presentations from NCI experts on screening, role of vaccines in prevention, and global tobacco control. Attendees also had the opportunity to learn more about the diverse milestones NCI has reached in global health research through a gallery walk of the GCR2016 poster session.
Month: November 2016
The Food and Drug Administration (FDA) has granted accelerated approval to olaratumab (Lartruvo®) for the treatment of some patients with soft tissue sarcoma.
The approval is for the use of olaratumab in combination with doxorubicin in patients with sarcoma that cannot be cured by radiation therapy or surgery and for whom anthracycline-based chemotherapy would be an appropriate treatment.
But cost-effective treatments could improve access to care, researchers say
HPV vaccine, safe sex practices would help reverse trend, cancer specialists say
Medical conditions, mental illness and substance abuse problems often overlap, researchers say
New report describes two melanoma patients who died of heart trouble after first doses of immunotherapy drugs
Leading cancer and women’s health groups say probably not
Researchers predict well over half a million lives would be saved over 50 years
Emulsifiers may change intestinal bacteria and promote inflammation, researchers say
Most choose treatment they originally planned to follow, study finds